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ABSTRACT – Purpose. We investigated elemental strontium and/or bisphosphonate drug incorporation upon 
the compositional and biomechanical properties of vertebral bone, in a rat model of Osteoporosis secondary to 
ovariectomy. Methods. Six month old female rats were ovariectomized (OVX) and divided into untreated OVX-
Vehicle, OVX-RIS (Risedronate bisphosphonate [BP] treated), OVX-SrR (Strontium Ranelate [Protos®] 
treated), combination OVX-RIS+SrR, and sham-operated controls. After 16 weeks of treatment, rats were 
euthanized and lumbar vertebra were dissected. Micro-Computed Tomography (micro-CT), Electron Probe 
Micro-Analysis (EPMA), mechanical testing in compression and nano-indentation testing were then undertaken 
to evaluate bone morphometry, elemental composition, material properties and strength. Results. Bone Volume 
was significantly reduced in the OVX-Vehicle (133±10mm3) compared with OVX-RIS (169±22mm3), OVX-
SrR (145±2mm3), and OVX-RIS+SrR (172±8mm3). EPMA mapped elemental Sr deposition to the periosteal 
surface of cortical bone (50-100 µm thick), endosteal trabecular surfaces (20 µm thick), as well as to both 
vertebral growth plates. The atomic ratios of (Ca+Sr)/P were significantly reduced with SrR treatment (2.4%-
6.6%), indicating Sr incorporation into bone mineral. No significant differences were measured in vertebral bone 
reduced modulus by nano-indentation. Conversely, all BP-dosed groups had significantly increased structural 
bone strength. Conclusions. Thus, we conclude that BP drugs dominate the conservation of trabecular geometry 
and structural strength in OP rats, whereas Sr drugs likely influence bone volume and material composition 
locally.  
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________ 
 
INTRODUCTION  
 
Osteoporosis (OP) related fractures affect one third of 
postmenopausal women worldwide, with an 
estimated 2 million OP related fractures occurring 
annually in the United States alone (1). Fracture 
occurs when bone encounters load of sufficient 
magnitude (and rate of loading) to exceed its 
mechanical strength. Currently, Bone Mineral 
Density (BMD) measurements derived from Dual-
Energy X-ray Analysis (DXA) are heavily relied 
upon in order to estimate bone strength for OP 
patients in the clinic. Using patient BMD to diagnose 
OP is based on the hypothesis that BMD is directly 
related to Young’s modulus (the isotropic elastic 
material property) of bone, and Young’s modulus is 
therefore used as an index of bone strength. However, 
as only 50-70% of fractures will be predicted based 
upon BMD measurements (2), it is clear that BMD 
values from DXA do not serve as the sole indicators 
of bone strength, and other important descriptors of 
bone quality and health (such as micro-architecture 
and material strength) need to be established, 
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accepted and factored into the patient assessment 
scheme. 
Both bisphosphonate (BP) and Strontium ranelate 
(SrR) drug regimens have been shown to reduce the 
incidence of bone fracture in OP patients in large 
multicenter clinical trials (3,4), and thus, both drugs 
are currently indicated for the treatment of OP 
worldwide (5,6,7). BPs are known to conserve 
trabecular bone volume and micro-architecture, and 
therefore bone strength. In contrast, SrR has attracted 
much attention due to claims of potential dual 
functionality, with reports of both antiresorptive & 
formative events in bone after treatment. Although 
BP drugs effectively block the resorption of bone, 
they are well known to interfere with the subsequent 
phase of coupled osteoblast activity, and reduce bone 
formation by up to 50% (8, 9). Conversely, studies 
suggest that SrR enhances osteoblastic cell function 
in remodeling and new bone growth (10, 11). 
Subsequent clinical studies indicated that SrR taken 
over a 3-year period resulted in the heterogeneous 
distribution of Sr in bone, resulting in the 
preservation of bone micro-structure at the tissue 
level – but not translating into increased stiffness, as 
measured by indentation modulus (12). Research has 
evaluated the effectiveness of SrR and BP treatments 
respectively over an extended period to determine the 
effect at both clinical and tissue mechanical level (12, 
13). However, there remains a lack of data on the 
chemical composition and material properties of bone 
tissue when those drugs are administered 
independently – or potentially in combination. 
Hence, the purpose of our study was to; (1) map 
the distribution and concentration of elemental 
Calcium, Strontium, and Phosphorus in bone (after 
BP and/or SrR drug treatments); (2) measure 
associated BMD and bone micro-architecture (by 
Micro-CT); (3) assess the material behavior of drug-
dosed bone (using nano-indentation); and (4) to 
combine those measurements of bone material 
property and micro-architecture to assess the 
outcomes of drug treatments from cohorts of bones in 
a rat model of developing OP. 
 
METHODS 
 
Animals and Drug Treatments 
Nineteen 6-month old female Sprague-Dawley rats 
were obtained from Charles River and maintained at 
the University of Alberta Biosciences Animal 
Services Facility. The protocol pertaining to all 
procedures and aspects of the study was approved by 
the University of Alberta animal care and ethics 
committee. Prior to being received at the facility, 16 
of the rats were ovariectomized (OVX), while the 
remaining 3 rats received a sham surgery and the 
ovaries remained intact. Upon arrival, the OVX rats 
were divided into 4 groups (n=4/group); OVX-
Vehicle (i.e., no drug treatment), OVX-RIS 
(Risedronate bisphosphonate [BP] treated), OVX-SrR 
(Strontium Ranelate [Protos®] treated), OVX-
RIS+SrR (combined treatment), and compared 
against the remaining group of age-matched Sham-
operated controls (n=3). 
The dosing of Risedronate Bisphosphonate was 
at 0.06 mg/kg, twice weekly, by subcutaneous 
injection. That corresponded to an established 
effective dose for preventing bone loss in this animal 
model as well as maintaining relevance to the dose 
currently used in BP treatment of osteoporosis in 
humans (14). The SrR was dosed at 308mg/kg once 
per day by oral gavage, in order to assure the 
minimum threshold concentration was achieved to 
show the potential antiresorptive properties of SrR 
(10, 15), while still trying to assess the SrR function 
at a concentration that could be regarded as clinically 
relevant for use in human patients (16). 
In rats dosed with RIS+SrR combination therapy, 
RIS was dosed s.c. 2 hours before giving the oral SrR 
dose, to allow for RIS to bind bone before strontium 
entered the system. One 2g sachet of commercially 
available SrR (Servier Laboratories, France) was 
reconstituted with distilled water and mixed to ensure 
dissolution. The rats were weighed and the calculated 
amount of stock solution was dosed daily by oral 
gavage using a gastric feeding needle. Those rats 
were fasted for two hours before and two hours after 
the dose to prevent any food interaction with calcium 
and any other elements within the feed. After 16 
weeks of treatment the rats were euthanized, and the 
L4, L5 and L6 were vertebral bones dissected fresh 
and cleaned of soft tissues, wrapped with Phosphate 
Buffer Saline (PBS)-dampened paper towel and 
stored frozen at -20°C for subsequent analyses. 
 
Micro-CT Imaging 
Dissected L4, L5 and L6 vertebrae were scanned ex 
vivo by micro-CT (Skyscan 1076, Kontich BE) at 
18µm resolution with 70kV, 100μA using a 1.0 mm 
Aluminum filter. Projected images of the samples 
were reconstructed using vendor supplied software 
(Nrecon 1.6.1.5, SkyScan NV, Kontich BE), with 
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images oriented in an axial plane of section. A 
rectangular region of interest (ROI) which was 
relative to the size of the vertebral body was used to 
sample a standardized amount of trabecular bone in 
the vertebral body in order to conduct standard 
histomorphometric analyses. The dimension of ROIs 
varied with the size of the vertebral body. The 
vertebral body growth plates were utilized as 
anatomical landmarks in order to consistently 
segment and sample the same region of trabecular 
bone from all samples. Vendor morphometric 
software (CTAn 1.10.0.1, SkyScan, Kontich BE) was 
then used to analyze trabecular bone volume (BV, 
mm3), fractal dimension (FD) (17), trabecular 
thickness (Tb.Th., mm) and trabecular separation 
(Tb.Sp., mm) and tissue mineral density (TMD, 
g/cm3) (18) against the vendor-supplied bone 
phantoms of known mineral density (0.25g/cm3 and 
0.75g/cm3) in order to calibrate BMD values from 
Hounsfield units. 
 
Electron Probe Micro-Analysis  
All L4 vertebrae were bisected coronally (Fig. 1) 
using an Isomet diamond wafer saw (Buehler Ltd., 
Lake Bluff IL) with the dorsal bone half reserved for 
subsequent nano-indentation testing. The ventral 
bone half was defatted in acetone for 2 weeks then 
dried in a 40°C oven and embedded in epoxy (Epo-
Kwick®, Buehler Ltd., Lake Bluff IL). Cylindrical 
molds 1 inch in diameter and height were used with 
the cut bone surface embedded facing down for fine 
grinding and polishing (~0.5μm) on an automated 
lapping plate. Sample surfaces were then coated with 
20-30nm thickness Carbon and electron probe micro-
analysis (EPMA) was undertaken with a Cameca 
SX100 electron probe (Cameca, Paris FR), equipped 
with both Wavelength Dispersive Spectroscopy 
(WDS) and Energy Dispersive Spectroscopy (EDS), 
using vendor supplied PeakSight 4.1 (Cameca, Paris 
FR) analysis software. Elemental calcium (Ca) Kα, 
strontium (Sr) Lα and phosphorus (P) Kα were 
analyzed in the same bony regions under 2μm 
resolution, 15kV and 15nA. The generated map size 
for one unit was 512 x 512 pixel as 1mm x 1mm. 
Strontianite EPS3 (SrCO3) and Apatite_639 
(Ca5(PO4)3F) standards were used to standardize 
subsequent quantitative analyses. PeakSight 4.1 
software was employed to calculate elemental Ca, Sr 
and P weight percent (wt%) against a reference 
spectrum, in order to measure both distribution and 
concentration. Quantitative elemental analysis was 
conducted after each scan with PAP oxide correction 
(19) to get quantities of wt% values from individual 
samples. Five point measures were randomly 
sampled and averaged for areas with Sr (periosteal 
surfaces of cortical bone) and without Sr (deeper 
cortical bone) for quantitative measurements. 
 
Nano-Indentation Testing 
The dorsal vertebral bone half was secured with 
modeling clay to orient and support the cut surface 
parallel to the indenter crosshead. Samples were 
glued to 15mm diameter specimen metal disks and 
surfaces polished to a depth of 15µm (0.05 µm 
progressively) then cleaned with flowing distilled 
water under ultrasonic agitation. Nano-indentation 
testing was conducted using the TI 900 TriboIndenter 
(Hysitron Inc., Minneapolis MN). We employed a 
Berkovich Tip for bone indentation testing, requiring 
conditioning (“tip bashing”) on a Quartz sample for 
1000 indentations, with subsequent machine 
compliance completed on aluminum. Shape Area 
function calibration was also performed on the 
Quartz sample in order to define the area function for 
subsequent modulus calculations. The Berkovich Tip 
(100-200nm radius, with angle from perpendicular to 
face = 65.35°; diamond material with Young's 
modulus = 1141Gpa, Poisson ratio = 0.07) was used 
to make 10 indentations on regions with and without 
Sr (Figs. 1b, c). Force control was 8000 µN with 5 
seconds of loading, 2 seconds holding and 5 seconds 
unloading. The Reduced modulus (Er) and Hardness 
(H) of each indentation were calculated from the 
unloading displacement-force curve based on the 
Oliver and Pharr method (20, 21). Er and H were 
calculated from the displacement-force curve in Fig. 
2, using the equations below, Eq. (1) - (4), where 
Pmax= maximum force, hmax= max contact depth, S = 
the stiffness while reaching the maximum force, hc= 
the intercept of the slope of the unloading curve with 
displacement axis, A(hc) = calibration of shape area 
function as a function of hc . 
 
S = (dP / dh)Pmax   (1) 
hc = hmax – (ƐPmax / S) ; for Berkovich geometry (Ɛ = 
0.75)     (2) 
Er =S π
1/2 / (2(A(hc))
1/2)   (3) 
H = Pmax / (A(hc))   (4) 
Indented bone regions were referred to the 
corresponding EPMA-derived elemental distribution 
maps, in order to compare the depth-force curves on 
regions of bone with (or without) Sr incorporation. 
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Anterior Posterior(A-P) view Dorsal block part (A-P view) Ventral  part (P-A view) 
  
  
Figure 1. (a) 3-D micro-CT render of rat L4 Vertebral bone, sectioned in the coronal plane. The ventral block 
was examined by EPMA, with the spatially registered dorsal block used for nano-indentation. (b) Regions of 
vertebral bone that underwent sequential nano-indentation (line of white dots), either with incorporated 
Strontium (EDGE), or without (CENTER). The light blue color indicates EPMA detection of elemental 
strontium. (c). Photomicrograph of triangular nano-indentations (Berkovich tip) on rat vertebral bone surface 
(Zeiss Axio CSM 700, 100x objective). 
 
Mechanical Testing 
L5 and L6 vertebra were thawed at room 
temperature, trimmed of bony processes using the 
diamond wafer saw, with transverse cuts applied to 
both metaphyseal growth plates. An Instron 4443 
materials testing device (Instron, Norwood USA) 
was used to test L5 and L6 vertebral body in axial 
compression under displacement control at a speed 
of 2mm/min, to avoid the effect of crosshead impact 
on the sample prior to failure. Load cell capacity 
was ±1kN with displacement recorded according to 
the position of the crosshead in mm, both with a 
resolution of 1E-5. Merlin™ Software and Series 
IX™ 8.0.7.0 vendor-supplied software (Instron, 
Norwood USA) were used to control testing and 
output the load deformation curve. Since the 
displacement-force curve were curved before, 
breaking energy (areas under the displacement-
force curve) was more objective to represent 
physical property of the bone than stiffness. It was 
then calculated to analyze the difference between 
treatment groups after BP and/or SrR treatments in 
the OVX rats. 
EDGE 
CENTER 
B
A 
B C 
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Figure 2. Force(P) – Displacement(h) Curve of 
nano-indentation tests.  
 
 
Statistical Analysis 
PASW® Statistics 17.0 was used for statistical 
evaluations. Due to the small sample numbers, non-
parametric Kruskal-Wallis H test was used to 
compare differences amongst groups, with the 
Mann-Whitney U test used to compare between 
individual groups. An asymptotic value ≤0.05 was 
used to test for significant differences. 
 
 
RESULTS 
 
Structural parameters from Micro-CT 
All drug treatment groups were measured to have 
significantly greater trabecular bone volume (BV) 
compared to untreated OVX-Vehicle (Table 1). The 
3-D FD values were increased in treatment groups 
where BV was also increased. However, we did not 
measure significant synergistic effects of BP+SrR 
treatments over the BP treatments individually, in 
either the BV or the FD values. According to the 
results of FD, SrR treatment increased the 
complexity of trabecular connectivity in OVX-SrR; 
however, the complexity was lower than for normal 
bone. Similarly, we did not measure significant 
differences in trabecular thickness (Tb.Th.) or BMD 
between the different treatment groups. From the 
micro-CT 3-D renders, we examined the trabeculae 
(FD, Tb.Sp.) and the thickness of cortical bone 
among groups. It was evident that OVX-RIS and 
OVX-RIS+SrR dosed animals had significant 
conservation of trabecular bone volume 4 months 
after OVX surgery (Fig. 3). 
 
Sr, Ca, P distributions and atomic ratio from 
EPMA  
From EPMA maps of different groups, we noted 
that Ca and P distributed evenly on the imaged 
surfaces (Fig. 4). Upon closer examination of 
individual trabeculae, we noted higher 
concentrations of Ca localized centrally in most 
trabeculae, with lower calcium concentrations 
localized as a thin layer on the exterior surfaces of 
both cortical and trabecular bone. Those 
observations suggested new bone formation events 
through appositional growth on the periosteal 
surface of cortical bone, and through remodeling on 
endosteal trabecular surfaces. Trabecular bone in 
proximity to the growth plate was also measured to 
have increased Ca concentration. Of particular 
significance was the dynamic localization of 
elemental Sr (using EPMA) to bone turnover in this 
animal model of OP (Fig. 5). The periosteal cortical 
bone in both the OVX-SrR and OVX-RIS+SrR 
groups exhibited layers of Sr-enriched appositional 
bone growth in the order of 50-100μm over the 16 
weeks period. Sr also deposited in trabecular bone 
distal to the growth plate (i.e., at the primary 
spongiosum). In EPMA maps of OVX-SrR, Sr 
incorporation encompassed individual trabeculae 
throughout the marrow cavity, to a depth of 
approximately 20μm. In stark contrast, Sr 
deposition was significantly reduced in the presence 
of the BP drug (i.e., in the OVX-RIS+SrR group), 
both in the number of formative events as well as in 
the depth of mineral deposition compared to SrR 
treatment alone. Quantitative analysis measured 
reduced wt% values in the OVX-RIS+SrR treated 
group for P2O5, CaO and SrO (48-80% of normal). 
In the Sr-free groups (i.e., Sham, OVX-Vehicle, 
OVX-RIS), no significant quantity of elemental Sr 
was measured. The Ca or Ca+Sr and P 
concentrations always maintained a consistent ratio. 
The atomic ratio (Ca/P or Ca+Sr/P) was 1.66 in all 
groups (Table 1). The examined average wt% of Ca 
is 29% and 14% for P. There was no significant 
difference of the Ca/P ratio among non-Sr treatment 
groups. In both Sr treated groups (OVX-SrR and 
OVX-RIS+SrR), we measured 2.4%-6.6% lower 
atomic ratio of (Ca+Sr)/P in comparison with non-
Sr groups. Accordingly, our data indicated that the 
wt% of Sr after 16 weeks of dosing with SrR (at the 
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dosage employed) resulted in less than 2% 
elemental Sr incorporation into the bone of the 
OVX-SrR and OVX-RIS+SrR groups. 
 
Depth-Force curves from Nano-Indentation tests 
Using nano-indentation, we did not measure any 
differences in reduced modulus or hardness after 16 
weeks of drug treatment at the drug dosages 
employed in this study. We also compared force-
displacement curves of nano-indentation on areas 
shown by EPMA with or without Sr 
(EDGE/CENTER of cortical bone) (Fig. 1b) 
relative to each group. The curves showed there 
were no significant differences among groups at 
areas of CENTER cortical bone under the given 
indentation conditions. We noted a non-significant 
trend of OVX-RIS samples exhibiting increased 
contact depth under the standardized loading 
conditions compared to all other treatment groups 
(Fig. 6). 
 
Mechanical Testing 
In contrast to nano-indentation, the breaking energy 
of global vertebral body compression in L5 and L6 
showed that both BP treated groups had increased 
structural bone strength compared with all other 
groups (Fig. 7). Both OVX-RIS and OVX-RIS+SrR 
dosed animals showed improved breaking energy 
compared to the other OVX groups (OVX-Vehicle 
and OVX -SrR).  
 
 
 
 
Table 1.Data of micro-CT , EPMA , nano-indentation and mechanical test 
 Treatment 
 Sham OVX-Vehicle OVX-RIS OVX-SrR OVX-RIS+SrR
micro-CT parameters of the average of L4,L5,L6 
BV (mm3) 153+11 b,e 133±10 a,c,d,e 169±22 b,d 145±2 b,c,e 172±8 a,b,d 
TMD (g/cm3) 0.65±0.05 0.64±0.01 0.67±0.02 0.65±0.02 0.65±0.01 
FD 2.48±0.04 b,d 2.36±0.03 a,c,e 2.53±0.03 b,d 2.41±0.02 a,c,e 2.54±0.02 b,d 
Tb.Th. (mm) 0.13±0.02 0.11±0.01 0.13±0.01 0.12±0.01 0.12±0.01 
Tb.Sp. (mm) 0.22±0.02 b,d 0.32±0.05 a,c,e 0.21±0.02 b,d 0.29±0.03 a,c,e 0.22±0.01 b,d 
EPMA atomic ratio of Sr,Ca and,P at Sr deposition region 
(Sr+Ca)/P 1.65±0.01 d,e 1.65±0.01 d,e 1.66±0.01 d,e 1.61±0.02 a,b,c 1.54±0.10 a,b,c 
Sr/P-HSr 0.00<0.00 d,e 0.00<0.00 d,e 0.00<0.00 d,e 0.03<0.00 a,b,c 0.03<±0.00 a,b,c 
Nanoindentation results of Reduced Modulus(Er) and Hardness(H) 
Er(GPa)-EDGE 31.52±6.62 31.78±3.68 23.82±3.80 31.10±6.85 29.85±5.73 
Er(GPa)-CENTER 33.02±2.90 32.63±3.53 30.55±5.45 36.28±2.10 33.78±1.26 
H(GPa)-EDGE 1.57±0.56 1.62±0.39 1.20±0.38 1.48±0.14 1.52±0.31 
H(GPa)-CENTER 1.62±0.17 1.61±0.14 1.42±0.47 1.96±0.34 1.73±0.14 
Mechanical  Testing  for Breaking Energy of L5,L6 
Breaking Energy (mm-kN) 0.19±0.01 0.18±0.04 0.23±0.07 0.19±0.01 0.27±0.03 
Data expressed as Mean±SD. aSignificantly different from Sham. bSignificantly different from OVX-Vehicle. 
cSignificantly different from OVX-RIS. dSignificantly different from OVX-SrR. eSignificantly different from OVX-
RIS+SrR. 
Abbreviations: BV: Bone Volume; TMD: Tissue Mineral Density; FD: Fractal Dimension; Tb.Th: Trabecular Thickness; 
Tb.Sp.: Trabecular Separation. 
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Figure 3. Upper panel: Cross-sectional images of Micro-CT in the coronal plane of L4 vertebral bodies. Lower panel: 3-
Dimensional renders of trabecular bone from a rectangular region of interest. 
 
 
 
Figure 4. Electron Probe Micro-Analysis (EPMA) maps of Calcium Distribution (Anterior-Posterior view of the half 
Vertebrae Body). Warmer colors indicate increased concentrations of elemental calcium. 
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Figure 5. Electron Probe Micro-Analysis (EPMA) maps of elemental strontium distribution (Coronal section of rat L4 
vertebral body). The light blue color indicates higher concentrations of elemental strontium. 
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(b) 
   
Figure 6. Depth (nm) vs. Load (µN) curves from nano-indentation tests of different groups. Curves of different groups are 
represented by different colors. a) Curves from indenting on EDGE. OVX-RIS shows a trend towards higher contact depth 
under the same indenting condition. b) Curves from indenting on CENTER. There were no apparent differences in contact 
depth between the treatments in the CENTER region of older, non-remodeling bone. 
Figure 7. The Breaking Energy of Rat Vertebrae L5, L6 tested under load (in compression) to failure. 
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DISCUSSION 
 
Bone fracture is a serious health concern with 
postmenopausal osteoporosis. Current BP 
antiresorptive drug interventions are highly 
effective at the conservation of existing bone 
volume, trabecular micro-architecture (and 
structural strength respectively), thereby preventing 
OP-related fracture during therapy. In our study, it 
was clear that the BP-treatment of OVX rats 
resulted in the significant conservation of bone 
volume and micro-architectural quality over all 
other treatment groups, which further translated into 
increased structural breaking energy during 
mechanical loading in compression. 
However, an extensive period of BP drug 
treatment may also introduce alterations in the 
remodeling (i.e., replenishing) ability of bone in the 
long term (22). Recent studies have reported the 
unexpected occurrence of spontaneous atypical 
subtrochanteric and diaphyseal femoral fractures in 
OP patients after long-term BP treatment (23), and 
those reports were reviewed by an ASBMR 
appointed task force (24). They concluded that the 
incidence of fracture associated with BP therapy for 
osteoporosis appears to be very low, and that a 
causal association has not been established. 
Amongst other recommendations, however, they 
encouraged further research in animal models to 
gather additional data to establish the true risk of 
BP use associated with conditions of catastrophic 
structural bone failure, which serves as a rationale 
for our current investigation. 
In contrast to BP drug therapy, SrR treatment 
(at the dose tested) did not increase the structural 
breaking energy of vertebral bone during 
mechanical loading in compression – despite 
showing some ability in the preservation of 
trabecular bone volume by ex vivo micro-CT. 
Those results agreed with published clinical 
findings showing that SrR taken over a 3-year 
period resulted in the preservation of bone micro-
structure at the tissue level, but did not translate into 
increased bone strength, as measured by indentation 
modulus (12). They also agreed with results by 
Bain et al who measured that bone stiffness in SrR-
treated animals was unchanged from values 
measured in OVX animals treated with vehicle – 
despite measuring the contrasting outcomes of 
dose-dependent higher maximal load, and the 
significant conservation of maximal energy to 
failure compared to OVX-untreated animals (25).  
Hence, the biological mechanism whereby SrR 
contributes to improve bone strength and anti-
fracture efficacy in clinical trials is still not entirely 
understood. Recent research by Boyd et al 
measured improved bone micro-architecture and 
reported an increase in stiffness in SrR treated rats 
as compared to controls (26). In that research, 
dosing with SrR commenced in growing, juvenile 
(i.e., 16 wk) normal Wistar rats, with a SrR dosage 
of 900mg/kg/day for 104 wks. They measured that 
SrR-treated rats did not show a decrease in bone 
strength compared to age-matched normal controls. 
However, it is difficult to compare those results to 
our study as we employed 6-month mature OVX 
Sprague-Dawley rats, with a significantly reduced 
dosage and duration of SrR (308 mg/kg/day for 16 
weeks) which nonetheless was previously reported 
to be at an effective dose range to effect both 
antiresorptive and anabolic activity (11,15). 
Our EPMA findings confirmed that in the 
normal rat, the mineralized bone matrix is 
heterogeneous in material composition with only 
trace amounts of elemental Sr uptake from the diet. 
In stark contrast, after SrR treatment, the Sr atom 
serves as a surrogate for elemental Ca uptake and 
was rapidly and heavily incorporated at sites of 
newly mineralizing bone. Those observations 
agreed with previously published reports on the 
incorporation and distribution of Sr in bone (27). In 
our study, profound regional differences in 
elemental composition were sensitively mapped to 
periosteal cortical and endosteal trabecular bone 
surfaces. Despite the significant increase in 
elemental Sr deposited in those regions of 
mineralized bone matrix, our mechanical testing 
evaluations of those same defined regions of Sr-
enriched bone using nano-indentation did not 
measure significant differences in bone tissue 
modulus, albeit confined to the SrR dosage we 
tested. 
The 4 month duration of SrR drug 
administration in our study was significantly less 
than that used in the clinical treatment of human 
patients with osteoporosis. Nonetheless, the 2 wt% 
of Sr deposition we measured was in accord with Sr 
deposition attained by taking higher dosages and 
treating patients for 3 years (12). Previous studies 
have concluded that SrR was effective in preventing 
rat OVX-induced bone loss and improving bone 
mechanical strength in doses as low as 125 
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mg/kg/day (11). In contrast, Fuchs et al suggested 
that a SrR dosage of 25mg/kg/day in the rat was 
comparable to the human dosage of 2g/day on a 
mg/kg basis. Their study also confirmed the 
25mg/kg/day dose levels produced serum levels of 
strontium similar to those found clinically (15), but 
they were not able to confirm the anabolic effect of 
SrR treatment in the OVX rat at the 25mg/kg/day 
dose. In a letter to the editor regarding that study, 
the authors were challenged in that the dose of SrR 
used was likely too low (i.e., sub-therapeutic)(28), 
and  referred to the dose of 308 mg/kg/day in an 
earlier published study as an effective dose that 
increased the trabecular bone volume by 30-36% 
(15). Indeed, in a more recent paper, 900mg/kg/day 
was used as a SrR dosage in rats to increase bone 
resistance and promote bone forming activity (26). 
That dose was stated to correspond to twice the 
human serum circulating level in rats based on 
pharmacokinetic measurements, but those 
statements were not supported by the evaluations 
reported in that paper. If an average postmenopausal 
osteoporosis patient is 70 kg, on a mg/kg basis that 
would translate to 63g of SrR per day. Thus, clearly, 
establishing clarity regarding the accuracy of 
pharmacokinetic and pharmacodynamic parameters 
surrounding SrR usage is of critical importance, as 
the current human clinical dose remains at the 2 g 
SrR p.o. once daily regimen (15).  
With our in vivo micro-CT analyses, we 
accurately measured the loss of trabecular bone 
mass and micro-architectural connectivity in 
vertebrae from untreated OVX animals developing 
OP. We found that SrR at the dose of 308 
mg/kg/day over 4 months significantly conserved 
vertebral trabecular bone volume compared to 
untreated OVX controls, however remained 
significantly less potent than OVX-RIS treated 
animals. Namely, in all BP treatment groups, we 
measured the significant conservation of BV, FD 
and Tb.Sp. compared to both untreated OVX 
controls and OVX-SrR dosed animals. Our bone 
mineral density (BMD) measurements did not show 
significant differences between any of the 
treatments, including that of SrR monotherapy 
(Table 1). In addition, we measured significantly 
reduced global (i.e., the entire bone sample) 
mechanical strength of vertebral bone in 
compression to failure in OVX rats, and the BP 
drug RIS (either as a monotherapy, or in 
combination with SrR) significantly improved the 
mechanical strength of OVX vertebral bone, 
whereas SrR was unable to significantly impact 
bone mechanical strength. 
Despite the ability for RIS treatment to preserve 
existing bone mass and micro-architectural 
structure, remodeled bone formation frequency and 
duration was significantly reduced in OVX-RIS 
dosed rats co-administered SrR, compared to OVX-
SrR dosed rats, as evidenced by EPMA analysis of 
incorporated elemental Sr. Thus, for remodeling 
BP-dosed bone, the significant reduction in 
trabecular matrix formation may alter the local 
volume and material composition of bone. In turn, 
that would potentially influence the anti-fracture 
strength, particularly if associated with thinning 
trabecular bone. 
One surprising finding of our study was the 
non-significant trend of OVX-RIS samples 
exhibiting increased contact depth under nano-
indentation compared to all other treatment groups. 
Clearly, BP drugs are known to increase global 
tissue modulus in great part through the 
conservation of bone volume and micro-
architectural connectivity, which serve to stiffen the 
bone in response to loading. However, it is 
important to note that our nano-indentation 
measurements were conducted in regions of newly 
formed bone (i.e., mineralized osteoid) that 
incorporated significant amounts of BP, SrR, or a 
combination of those drug molecules. Thus, the 
localized presence of those drugs likely influenced 
cellular biology and bone matrix formation in a 
“site-specific” manner. 
There are several limitations of this preliminary 
study. Firstly, the sample number per treatment 
group remained small, due to the complexity and 
expense of coordinating precise regional analyses of 
drug-dosed bone regions between the micro-CT, 
EPMA and nano-indentation techniques that were 
employed. However, as our study purpose was to 
contrast the material and compositional make-up of 
bone after BP and/or SrR drug therapy in an animal 
model of OP, our findings should remain of interest. 
Another study limitation was that our nano-
indentation facility is limited to the indention of dry 
bone samples. Therefore, the depth-displacement 
curves of dried samples will likely be stiffer than 
that measured with hydrated samples, although 
bone samples from each group were treated and 
dried using the same procedure. Thus, comparison 
of our measured values to those from other facilities 
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may differ in magnitude, as the procedure for 
sample preparation, testing and handling will differ. 
We conclude that BP drugs dominate the 
conservation of trabecular geometry and 
corresponding structural bone strength in OP rats, 
whereas SrR may influence bone volume and 
material composition locally. The administration of 
SrR and the subsequent uptake of Sr appeared to 
have less of an impact on the structural integrity of 
bone as it did on the utility of its presence in 
permitting new bone formation during the 
remodeling cycle. The incorporation of BP and/or 
Sr drugs (at the dosages used) did not increase the 
mechanical stiffness of bone matrix in locations 
known to contain those drugs, and remained similar 
to values measured in sham-operated controls. 
Our study further highlights the potential that Sr 
drugs offer for use as exquisite indicators of bone 
turnover. Perhaps it is the non-ionizing, tracer 
potential observed when administering sub-
therapeutic quantities of SrR that could prove of 
greatest utility for clinicians in the assessment and 
understanding of regional bone turnover for 
individual patients. Further studies will help shed 
light on the diagnostic tracer utility of Sr based 
compounds that may eventually find use as 
effective clinical diagnostic tools in the diagnosis 
and treatment of bone injury, repair and disease. 
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